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PSG7
POSTOPERATIVE PAIN RELIEF, INTERFERENCE 
WITH ACTIVITIES, AND SATISFACTION: 
PRELIMINARY RESULTS
Strassels S1, Chen C2, Carr D1, McDonagh M1, Gouveia W1, 
Wurm H1
1New England Medical Center, Boston, MA, USA; 2Searle 
Pharmaceuticals, Skokie, IL, USA
Postoperative pain is suboptimally controlled for many
people; however, limited information is available about
pain from the patient’s perspective. OBJECTIVES: A
purpose of this observational pilot study was to describe
patient’s postoperative pain relief and their satisfaction
with their care after common abdominal or orthopedic
surgical procedures. METHODS: Within 24 hours be-
fore discharge from the hospital after total abdominal
hysterectomy (TAH), or total hip or knee replacement
(THR, TKR), patients completed a new survey that in-
cluded a modified version of the American Pain Society
(APS) Quality Improvement Questionnaire. Percent pain
relief and pain-related interference with activities were
rated on a 0 (0% relief, no interference)–10 (100% relief,
maximum interference) analog scale. Satisfaction with
pain treatment was rated on a six-point Likert scale.
Data were collected between August and November
1999. RESULTS: Mean percent pain relief from analge-
sics was at least 70% for all persons in each surgical
group and overall. On average, pain interfered most with
sleep (5.4/10) for TAH and THR patients, and 6.7/10 for
TKR patients, and with walking ability for THR (5.0/10)
and TKR (5.8/10) patients. Of TAH patients, 42.9% re-
ported being slightly dissatisfied, and 57.1% reported be-
ing satisfied with their pain care. All THR patients and
more than 82% of TKR patients were satisfied or very
satisfied with their pain treatment. CONCLUSION: Al-
though pain interfered with sleep and other activities,
most patients were satisfied with their pain care. Pain lev-
els and pain-related interference with activities may be re-
lated to suboptimal analgesic doses or dosing frequency.
PSG8
LONG-TERM OUTCOMES AND RESOURCE USE 
ASSOCIATED WITH MYOMECTOMY
Subramanian S, Clark MA, Quinn VC
Boston Scientific Corporation, Natick, MA, USA
Myomectomy is the most commonly performed proce-
dure for women with large fibroids who want to preserve
their uterus. Since myomectomy is associated with a 15–
30% rate of fibroid recurrence, a systematic assessment
of long-term resource use is critical for evaluation but to
date no comprehensive analyses have been performed.
OBJECTIVE: To evaluate the long-term outcomes and
cost of myomectomy through retrospective claims data
analysis. METHODS: The study was performed using
the MEDSTAT MarketScan private pay fee-for-service
database for the years 1995, 1996, and 1997. Patients
were selected for analysis based on the presence of ICD-
9-CM procedure and/or CPT-4 codes associated with
myomectomy. In addition, diagnosis of uterine fibroids
and related symptoms for these patients were confirmed
through ICD-9-CM diagnosis codes. Inpatient, outpa-
tient, physician, and pharmacy data for all three years
were combined into a single file using unique patient
identifiers. All cost data were converted to 1997 dollars.
RESULTS: A total of 3,730 women, between the ages of
19 and 62, were available for analysis. Of these, 39%
had an inpatient admission while the remaining only had
outpatient procedures. The estimated cost of an abdomi-
nal myomectomy procedure was $7,551 and that of a
vaginal myomectomy was $3,136. Preliminary analysis
indicates that at least 8% of the women had an addi-
tional procedure within a year and a higher percentage in
subsequent years. There were also a high number of fi-
broid-related outpatient visits and some prescription medi-
cation use. CONCLUSION: The high number of repeat
procedures, outpatient visits, and prescription medica-
tion add significantly to total cost and highlight the im-
portance of assessing overall health care utilization. This
comprehensive analysis facilitates the systematic evalua-
tion of myomectomy with emerging alternative treat-
ments for uterine fibroids.
PSG9
CLINICAL AND ECONOMIC OUTCOMES OF 
CORONARY ANGIOPLASTY ALONE OR IN 
COMBINATION WITH STENTS IN ACADEMIC 
HEALTH CENTERS: A RETROSPECTIVE 
DATABASE ANALYSIS
Oinonen MJ1, Akhras KS2, Chen C2, Matuszewski KA1, 
Vlasses PH3
1University HealthSystem Consortium, Oak Brook, IL, USA; 
2Searle, Skokie, IL, USA; 3American Council on Pharmaceutical 
Education, Chicago, IL, USA
Indications for the use of coronary stents are evolving
and their optimal place in therapy remains to be defined.
OBJECTIVE: The purpose of this analysis was to com-
pare the one-year clinical and economic outcomes of per-
cutaneous transluminal coronary angioplasty (PTCA)
with or without the use of stents. METHODS: This ret-
rospective database analysis from 60 US academic medi-
cal centers in 1996 and 1997 included 27,020 patients
that either did (n  13,254) or did not (n  13,766) re-
ceive stents in conjunction with PTCA. Outcomes of in-
terest included in-hospital mortality (both on sentinel
and readmission visits), readmission rates, revasculariza-
tion procedures, length of stay, and the cost of sentinel
and readmission hospitalizations. RESULTS: The median
hospitalization cost for the stent group was about $1409
higher than for the no-stent group, even though they had
similar lengths of stay (4.3 days vs. 4.5 days respectively,
P  0.001). While mortality rates on readmissions (0.9%
stent vs. 0.8% no-stent, p  NS) did not differ, stent
placement during the sentinel event was associated with
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improved survival (1.7% vs. 2.7%, P  0.001). In multi-
variate analysis, stent use was not associated with a sig-
nificantly lower risk of a revascularization procedure on
readmission to the same institution [OR 0.95, 95% CI
(0.87–1.04), P  0 .28]. From the health care system’s
perspective, 106 patients would need to be treated with a
stent to prevent one death on sentinel admission. CON-
CLUSION: Stent use decreased in-patient mortality by
1% without impacting length of stay or readmission
rates. At $149,354 per life year saved, stents would need
to increase a person’s life expectancy by a minimum of
three years over that which is gained from PTCA alone to
remain a cost-effective alternative.
PSG10
RESTENOSIS AND MEDICAL COSTS 
FOLLOWING PERCUTANEOUS TRANSLUMINAL 
CORONARY ANGIOPLASTY (PTCA) WITH AND 
WITHOUT STENT
Sen S1, Khandker R2, Roth D2, Thomas J1
1School of Pharmacy, Purdue University, West Lafayette, IN, 
USA; 2SmithKline Beecham, Collegeville, PA, USA
Data is available on stent PTCA restenosis rates in RCTs
but little data is available on restenosis rates and medical
costs in actual practice. OBJECTIVES: To compare rest-
enosis rates (repeat PTCA or stent, coronary artery by-
pass grafting, or myocardial infarction) and medical care
costs during one year post-PTCA for patients with and
without stents. METHODS: A total of 1756 patients
with index PTCA during 1995 and no PTCA in the prior
1 year were identified from a medical claims database of
large self-insured plans covering 1.7 million lives. Stents
were received by 373 of 1756 PTCA patients during the
index PTCA. RESULTS: Restenosis occurred in 316
(22.8%) of 1383 non-stent patients versus 62 (16.6%) of
373 (P  0.001) stent patients. For the one-year period
following index PTCA, ischemic heart disease (IHD)-
related medical costs were not significantly different be-
tween stent (mean  $5898,) and non-stent (Mean 
$7018) groups (P  0.18) nor did total medical costs dif-
fer among stent (Mean  $14,128) and non-stent (Mean 
$13,621) groups (P  0.71). Logistic regression (includ-
ing: age, gender, comorbidities, prior year hospitaliza-
tions, percent of IHD hospitalizations in prior year,
PTCA length of stay, and inpatient-PTCA) revealed
lower probability of restenosis (odds ratio  0.7, P 
0.02) in stent patients. Cost regressions using the same
covariates revealed no significant difference in IHD re-
lated costs or total medical costs for the one year period
following index PTCA. CONCLUSIONS: Although stented
patients had lower restenosis rates, 1-year medical costs
following PTCA were not significantly different based on
stenting.
PSG11
COST ANALYSIS OF INHALED AGENTS IN 
CANADIAN PEDIATRIC HOSPITALS
Bussières JF, Giguère M
Hôpital Sainte-Justine, Montreal, QC, Canada
Inhaled agents and propofol are used to sedate patients
for surgical interventions. Economic analysis of these
agents is complex and includes acquisition cost, wastage,
adjuvants, flow rate of fresh gas, equipments, and pa-
tient-specific factors. OBJECTIVES: The study purpose
was to benchmark annual costs of halothane, isoflurane,
desflurane, sevoflurane, enflurane, thiopenthal and pro-
pofol in Canadian pediatric institutions. METHODS: A
written survey was sent to 9 major hospital pharmacy de-
partments in 1999 with 2 recalls regarding the 1997–98
and 1998–99 fiscal years. RESULTS: Response rate was
78% (7/9). Our cohort includes a total 1005 beds,
48,659 admissions/year and 64,552 surgical procedures/
year. Day surgery represents 31% of total cases. Inhaled
agents and propofol represented 47.4% (n  7, sd  8.1)
of total drug costs in operating room (OR) and recovery
room (RR). Anesthetic agents costs were on average
$0.18 CAN/min of surgery (n  4, sd  0.05) in 1997–
98 and $0.21 CAN/min (n  3, sd  0.13) in 1998–99.
Total costs/patient of all drugs used were $430.26 CAN
(n  4, sd  8.8) in 1997–98 and $26.11 CAN (n  4,
sd  6.28) in 1998–99. Total costs/patient for anesthetic
agents were $13.54 CAN (n  4, sd  2.7) in 1997–98
and $12.48 CAN (n  4, sd  1.98) in 1998–99. Costs
reduction seems to be mainly caused by price reduction
of isoflurane for 1998–99 which went from 1st position
in 1997–98 ($171,610 CAN, n  5) to 3rd position in
1998–99 ($116,700 CAN, n  5) even with a 10% in-
crease in consumption. Total costs of these agents
increased by 3.5%. Sevoflurane has taken the 1st position
in 1998–99. CONCLUSION: There are little data avail-
able in the literature to allow benchmarking in the pedi-
atric OR. Further studies are required to identify the best
ratio useful to monitor such costs as well as relevant out-
comes.
PSG12
HOSPITAL COST SAVINGS FROM SEVERITY-
ADJUSTED LENGTH OF STAY FOLLOWING 
SURGERY FOR INTRA-ABDOMINAL INFECTION 
AND TREATMENT WITH PIPERACILLIN/
TAZOBACTAM OR IMIPENEM/CILASTATIN
Bjerke S1, Mallick R2, Clark K2, Wible M2, Zito E2, Guttman 
R2, Sillup G2
1Methodist Hospital of Indianapolis, Indianapolis, IN, USA; 
2Wyeth-Ayerst Research, Radnor, PA, USA
BACKGROUND: Treatment of intra-abdominal infec-
tions (IAI) has important health economic components
including hospital stay and the cost and administration of
pharmaceuticals. METHODS: From the hospital’s per-
spective, time-to-discharge (TTD) was evaluated for 258
